Literature DB >> 1394140

Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.

E Andrejauskas-Buchdunger1, U Regenass.   

Abstract

The microbial alkaloid staurosporine is a potent but nonselective inhibitor of protein kinases. The derivative CGP 41251 has been shown to exert a high degree of selectivity for inhibition of protein kinase C activity. Both compounds are powerful inhibitors of proliferation of both normal and transformed cells in vitro and exert antitumor efficacy in vivo. In this work we have studied the mode of action of these compounds by analyzing their effects on early events in the induction of proliferation by different growth stimuli. Both drugs blocked the phorbol ester-induced expression of the c-fos proto-oncogene. The effect of CGP 41251 was reversible, since its removal led to a normal expression of c-fos mRNA in response to phorbol 12-myristate 13-acetate. Submicromolar concentrations of CGP 41251 and staurosporine directly inhibited both the platelet-derived growth factor (PDGF) receptor autophosphorylation and the c-fos mRNA expression induced by PDGF stimulation of intact BALB/c 3T3 cells. In contrast, ligand-induced epidermal growth factor receptor autokinase activity in A431 carcinoma cells and epidermal growth factor-dependent c-fos mRNA expression were relatively insensitive to inhibition by CGP 41251. Staurosporine suppressed signal generation by the epidermal growth factor receptor by reducing overall levels of the receptor. We conclude that CGP 41251 is a potent reversible inhibitor of protein kinase C and PDGF-mediated signal transduction. It inhibits the kinase activity of both protein kinase C and the PDGF receptor tyrosine kinase and the subsequent signaling cascade. The broad inhibition of kinases by staurosporine is also reflected at the cellular level and might contribute to the high toxicity of this compound, in comparison to CGP 41251.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394140

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

Authors:  R van Gijn; O van Tellingen; E Haverkate; J J Kettenes-van den Bosch; A Bult; J H Beijnen
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro.

Authors:  I F Pollack; S Kawecki
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

3.  Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.

Authors:  P Furet; T Meyer; P Mittl; H Fretz
Journal:  J Comput Aided Mol Des       Date:  2001-05       Impact factor: 3.686

4.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Authors:  E Buchdunger; J Zimmermann; H Mett; T Meyer; M Müller; U Regenass; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

6.  Protein kinase C and adenylate cyclase as targets for growth inhibition of human gastric cancer cells.

Authors:  M Piontek; K J Hengels; R Porschen; G Strohmeyer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.

Authors:  Jing Chen; Nathan R Wall; Kerry Kocher; Nicole Duclos; Doriano Fabbro; Donna Neuberg; James D Griffin; Yang Shi; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

8.  Hypoxia-induced accumulation of erythropoietin mRNA in isolated hepatocytes is inhibited by protein kinase C.

Authors:  K U Eckardt; A Ring; M Maier; B Gess; D Fabbro; A Kurtz
Journal:  Pflugers Arch       Date:  1994-01       Impact factor: 3.657

9.  Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.

Authors:  Noemi Kedei; Nancy E Lewin; Tamás Géczy; Julia Selezneva; Derek C Braun; Jinqiu Chen; Michelle A Herrmann; Madeleine R Heldman; Langston Lim; Poonam Mannan; Susan H Garfield; Yam B Poudel; Thomas J Cummins; Arnab Rudra; Peter M Blumberg; Gary E Keck
Journal:  ACS Chem Biol       Date:  2013-02-01       Impact factor: 5.100

10.  4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

Authors:  E Buchdunger; U Trinks; H Mett; U Regenass; M Müller; T Meyer; E McGlynn; L A Pinna; P Traxler; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.